Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2334595 | 0.85 | CYSLTR2 (0.52) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL6798820 | 0.83 | CYSLTR2 (0.53) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL6835106 | 0.80 | PDE10A (0.62) | PDE10ACYP1A2CYP2C9 | |
| SCHEMBL2913941 | 0.79 | PDE10A (0.61) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL8503996 | 0.79 | CYSLTR1 (0.50) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL3028085 | 0.79 | PDE10A (0.46) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL9598037 | 0.79 | CYSLTR1 (0.46) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL8906354 | 0.79 | PDE10A (0.47) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL9479707 | 0.79 | PDE10A (0.46) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL4866792 | 0.79 | HRH1 (0.49) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053598-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| EP-1745014-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20090012171-A1 | Novel Compounds, Their Preparation and Use | NOVO NORDISK A/S (CZ) | 2009-01-08 | — | — | US | disclosed |
| EP-1745014-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105736-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012171-A1 | Novel Compounds, Their Preparation and Use | PPARG, PPARD, PPARA | PDE10A 506/4885CYSLTR2 572/4885CYSLTR1 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.